“We are excited to initiate the Phase 3 study and we believe that Piclidenoson’s oral dosage and excellent safety record, together with its progressive effectiveness over time, make it an ideal drug ...

Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...

Fact checked by Nick Blackmer I love living in New England, where I experience all four seasons. Winters are snowy and ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Join Drs Steven Feldman and Robert Kushner as they discuss the role of dermatologists in treating obesity in conjunction with psoriasis.

Join Drs Steven Feldman and Jules Lipoff as they discuss teledermatology, the cost of prescriptions, and other barriers to ...

Discover how psoriasis affects immune function and the role of SSAT1 in this chronic skin condition. Learn more now.

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

SFA-002 met its exploratory endpoint of efficacy. Patients administered SFA-002 demonstrated statistically significant Psoriasis Area and Severity Index (PASI) percentage change and Investigator ...